GlassScriptPhysician profile
Brittney Atheras
NPI 1992339634
$8,047.40
in general payments reported to CMS, 2019-2025
59 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,020 · 2022: $1,832 · 2023: $2,555 · 2024: $1,529 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,983 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,982.70 |
| Education | $212.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $586.03 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $491.40 | 2022-2025 | Enhertu, Injectafer, Vanflyta |
| Gilead Sciences, INC. | $480.60 | 2022-2025 | Trodelvy |
| Janssen Biotech, INC. | $389.48 | 2021-2025 | Rybrevant, Carvykti, Tecvayli |
| Astellas Pharma US INC | $356.57 | 2021-2025 | Padcev, Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $354.18 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $331.82 | 2021-2025 | Enhertu, Calquence, Lynparza |
| Seagen INC. | $331.62 | 2021-2023 | Padcev, Tukysa |
| Amgen INC. | $319.64 | 2021-2023 | Nplate, Xgeva, Lumakras |
| Novartis Pharmaceuticals Corporation | $318.51 | 2023-2025 | |
| Eisai INC. | $314.46 | 2021-2025 | |
| Incyte Corporation | $262.44 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Abbvie INC. | $259.51 | 2021-2025 | |
| Glaxosmithkline, LLC. | $182.08 | 2021-2025 | Jemperli, Zejula |
| Servier Pharmaceuticals LLC | $163.71 | 2022-2025 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $162.03 | 2021-2025 | Opdivo, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $154.74 | 2021-2025 | Ninlaro, Alunbrig, Vpriv |
| Celgene Corporation | $153.14 | 2021-2025 | Reblozyl, Pomalyst |
| Genentech USA, INC. | $139.07 | 2022-2025 | Polivy, Tecentriq, Venclexta |
| Karyopharm Therapeutics INC. | $137.89 | 2022-2025 | Xpovio |
| Pfizer INC. | $137.81 | 2021-2025 | |
| Lilly USA, LLC | $135.94 | 2022-2025 | Retevmo, Jaypirca, Verzenio |
| Coherus Oncology, INC. | $120.55 | 2021-2025 | Loqtorzi |
| Pharmacosmos Therapeutics INC. | $114.84 | 2021-2024 | Monoferric |
| Taiho Oncology, INC. | $109.02 | 2023-2025 | |
| Genzyme Corporation | $106.22 | 2021-2023 | |
| Mirati Therapeutics, INC. | $87.37 | 2023-2024 | Krazati |
| G1 Therapeutics, INC. | $82.63 | 2022-2023 | Cosela |
| Foundation Medicine, INC. | $81.61 | 2022 | |
| Puma Biotechnology, INC. | $79.50 | 2022-2025 | |
| Genmab U.S., INC. | $75.39 | 2023-2025 | Tivdak |
| Regeneron Healthcare Solutions, INC. | $73.12 | 2021-2025 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.47 | 2021-2023 | Gilotrif |
| Emd Serono, INC. | $69.62 | 2022-2024 | Tepmetko, Bavencio |
| Ipsen Biopharmaceuticals, INC | $69.54 | 2024 | Onivyde, Somatuline Depot |
| Morphosys, US INC. | $58.16 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $57.07 | 2022-2024 | |
| Geron Corporation | $51.78 | 2025 | Rytelo |
| Dendreon Pharmaceuticals LLC | $51.19 | 2021-2023 | Provenge |
| Stemline Therapeutics INC. | $51.12 | 2022-2023 | Orserdu |
| Sobi, INC | $48.05 | 2022-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $42.03 | 2021 | |
| Adaptive Biotechnologies Corporation | $37.88 | 2022-2025 | Clonoseq |
| Rigel Pharmaceuticals, INC. | $37.54 | 2024 | Rezlidhia, Tavalisse |
| Array Biopharma INC | $34.37 | 2022 | |
| Tersera Therapeutics LLC | $33.76 | 2021-2025 | Xermelo |
| Kyowa Kirin, INC. | $31.43 | 2022-2023 | Poteligeo |
| Immunogen, INC. | $27.87 | 2023-2024 | Elahere, Elahere |
| Jazz Pharmaceuticals INC. | $23.67 | 2021 | |
| Adc Therapeutics America, INC. | $21.34 | 2024 | |
| Pharmaessentia USA Corporation | $18.26 | 2025 | Besremi |
| Boston Scientific Corporation | $17.98 | 2025 | Wavewriter Alpha Prime 16 |
| Deciphera Pharmaceuticals INC. | $16.71 | 2023 | Qinlock |
| Blueprint Medicines Corporation | $14.89 | 2022 | |
| Myriad Genetic Laboratories, INC. | $14.82 | 2024 | Myrisk |
| Beigene USA, INC. | $13.91 | 2022 | |
| Myovant Sciences INC. | $13.80 | 2022 | |
| Aimmune Therapeutics, INC. | $13.76 | 2024 | |
| Epizyme, INC. | $13.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittney Atheras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.